A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males

This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).

Inclusion Criteria:

• Participant has androgenetic alopecia (AGA)
• Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.

Exclusion Criteria:

• History of hair loss for reasons other than AGA
• Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
• Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
• Hair-weaving within 6 months
• Use of hair colorants or dyes within 6 months.